Eli Lilly And Stock Filter Stocks by Fundamentals
LLY Stock | USD 777.96 0.22 0.03% |
Eli Lilly And fundamentals help investors to digest information that contributes to Eli Lilly's financial success or failures. It also enables traders to predict the movement of Eli Stock. The fundamental analysis module provides a way to measure Eli Lilly's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eli Lilly stock.
Eli | Cash Flow from Operations |
Eli Cash Flow from Operations Analysis
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 16.9B | 16.2B | 25.2B | 26.5B | Total Assets | 48.8B | 49.5B | 64.0B | 67.2B |
Eli Cash Flow from Operations Driver Correlations
Understanding the fundamental principles of building solid financial models for Eli Lilly is extremely important. It helps to project a fair market value of Eli Stock properly, considering its historical fundamentals such as Cash Flow from Operations. Since Eli Lilly's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eli Lilly's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eli Lilly's interrelated accounts and indicators.
Click cells to compare fundamentals
Competition |
Eli Discontinued Operations
Discontinued Operations |
|
In accordance with the recently published financial statements, Eli Lilly And has 0.0null in Cash Flow from Operations. This indicator is about the same for the Pharmaceuticals average (which is currently at 0.0) sector and about the same as Cash Flow from Operations (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Fundamental Analysis Now
Fundamental AnalysisView fundamental data based on most recent published financial statements |
All Next | Launch Module |
Eli Lilly ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eli Lilly's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eli Lilly's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Eli Fundamentals
Return On Equity | 0.48 | ||||
Return On Asset | 0.12 | ||||
Profit Margin | 0.15 % | ||||
Operating Margin | 0.34 % | ||||
Current Valuation | 759.05 B | ||||
Shares Outstanding | 950.77 M | ||||
Shares Owned By Insiders | 0.16 % | ||||
Shares Owned By Institutions | 84.34 % | ||||
Number Of Shares Shorted | 5.42 M | ||||
Price To Earning | 54.92 X | ||||
Price To Book | 68.40 X | ||||
Price To Sales | 21.59 X | ||||
Revenue | 34.12 B | ||||
Gross Profit | 21.91 B | ||||
EBITDA | 12.46 B | ||||
Net Income | 5.24 B | ||||
Cash And Equivalents | 2.07 B | ||||
Cash Per Share | 2.97 X | ||||
Total Debt | 25.23 B | ||||
Debt To Equity | 1.58 % | ||||
Current Ratio | 1.13 X | ||||
Book Value Per Share | 11.98 X | ||||
Cash Flow From Operations | 4.24 B | ||||
Short Ratio | 1.45 X | ||||
Earnings Per Share | 5.81 X | ||||
Price To Earnings To Growth | 1.47 X | ||||
Target Price | 809.74 | ||||
Number Of Employees | 43 K | ||||
Beta | 0.34 | ||||
Market Capitalization | 736.75 B | ||||
Total Asset | 64.01 B | ||||
Retained Earnings | 10.31 B | ||||
Working Capital | (1.57 B) | ||||
Current Asset | 12.57 B | ||||
Current Liabilities | 8.23 B | ||||
Z Score | 18.9 | ||||
Annual Yield | 0.01 % | ||||
Five Year Return | 1.83 % | ||||
Net Asset | 64.01 B | ||||
Last Dividend Paid | 4.52 |
About Eli Lilly Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eli Lilly And's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eli Lilly using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eli Lilly And based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Eli Lilly operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 35000 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Eli Lilly Piotroski F Score and Eli Lilly Altman Z Score analysis. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.13 | Dividend Share 4.52 | Earnings Share 5.81 | Revenue Per Share 37.908 | Quarterly Revenue Growth 0.281 |
The market value of Eli Lilly And is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.